Edition:
United Kingdom

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

2.73USD
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
$2.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
223,349
52-wk High
$36.25
52-wk Low
$1.70

Latest Key Developments (Source: Significant Developments)

Altimmune Files For Mixed Shelf Of Upto $250 Mln
Thursday, 4 Apr 2019 

April 4 (Reuters) - Altimmune Inc ::ALTIMMUNE INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING.  Full Article

Altimmune Announces Financial Results For Year Ended Dec 31
Monday, 1 Apr 2019 

April 1 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2018 AND PROVIDES CORPORATE UPDATE.  Full Article

Altimmune says Cash, Cash Equivalents And Restricted Cash As Of Dec. 31 Is $34.4 Mln
Friday, 8 Mar 2019 

March 8 (Reuters) - Altimmune Inc ::ALTIMMUNE INC - PRELIMINARY NET LOSS PER SHARE FOR THE YEAR ENDED DECEMBER 31, 2018, $14.87 TO $15.23.ALTIMMUNE INC - PRELIMINARY REVENUE FOR THE YEAR ENDED DEC 31, 2018 $10 –10.5 MILLION.ALTIMMUNE INC - CASH, CASH EQUIVALENTS AND RESTRICTED CASH AS OF DECEMBER 31, 2018 IS $34.4 MILLION.  Full Article

Altimmune Announces Clinical Program Updates And Plans For Pipeline Expansion
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES CLINICAL PROGRAM UPDATES AND PLANS FOR PIPELINE EXPANSION.ALTIMMUNE INC - ADVANCING MANUFACTURE OF A MULTIVALENT FORMULATION AND INTENDS TO INITIATE ADDITIONAL PHASE 2 STUDIES ONCE MANUFACTURING IS COMPLETE.ALTIMMUNE - CONDUCTING EXTENSION STUDY FOR PREVIOUS PHASE 2A STUDY PARTICIPANTS TO GAUGE FURTHER DURABILITY OF HAI RESPONSES A YEAR AFTER VACCINATION.ALTIMMUNE INC - WILL BE EVALUATING OTHER CLINICAL MEASURES OF NASOVAX IMMUNOGENICITY.ALTIMMUNE INC - INTENDS TO PURSUE ADDITIONAL COMPLEMENTARY INDICATIONS FOR ITS DIFFERENTIATED SYNTHETIC IMMUNOTHERAPEUTIC PEPTIDE TECHNOLOGY.ALTIMMUNE INC - CO PLANS TO EXPLORE OPPORTUNITIES TO EITHER ACQUIRE PRODUCTS OR PARTNER IN NOVEL IMMUNOTHERAPY INDICATIONS TO FURTHER EXPAND PIPELINE.ALTIMMUNE INC - PLANS TO ADVANCE HBV-SPECIFIC IMMUNE ACTIVATION BY HEPTCELL INTO PHASE 2 DEVELOPMENT.  Full Article

Altimmune Says William Enright To Resign As President, CEO Of Co And Member Of Board
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Altimmune Inc ::ALTIMMUNE SAYS ON OCT 16 WILLIAM ENRIGHT NOTIFIED BOARD THAT HE INTENDS TO RESIGN AS PRESIDENT, CEO OF CO AND MEMBER OF BOARD - SEC FILING.ALTIMMUNE SAYS ENRIGHT STATED THAT HIS DECISION TO RESIGN INVOLVED A DISAGREEMENT OVER SCOPE OF HIS RESPONSIBILITIES AT CO.ALTIMMUNE INC - CO, ENRIGHT HAVE AGREED THAT ENRIGHT WILL REMAIN PRESIDENT, CEO UNTIL EARLIER OF APPOINTMENT OF HIS SUCCESSOR OR FEB 28, 2019.ALTIMMUNE INC - ENRIGHT WILL ALSO REMAIN ON BOARD UNTIL HIS RESIGNATION AS PRESIDENT AND CEO IS EFFECTIVE.ALTIMMUNE - ENRIGHT'S DECISION TO RESIGN IS NOT OTHERWISE RESULT OF ANY DISAGREEMENT ON ANY MATTERS RELATING TO CO'S OPERATIONS, POLICIES/PRACTICES.ALTIMMUNE INC - BOARD HAS BEGUN A PROCESS TO IDENTIFY ENRIGHT'S SUCCESSOR.  Full Article

Altimmune Announces $4.9 Mln Registered Direct Offering
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES $4.9 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK.ALTIMMUNE INC - REGISTERED DIRECT OFFERING OF 286,633 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $17.02 PER SHARE.ALTIMMUNE INC - TO USE NET PROCEEDS FROM THIS OFFERING FOR CONTINUED ADVANCEMENT OF DEVELOPMENT ACTIVITIES FOR OUR CLINICAL-STAGE PRODUCT PIPELINE.  Full Article

Altimmune Announces Additional Positive Data From Its Phase 2A Study Of NasoVAX Intranasal Influenza Vaccine
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES ADDITIONAL POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE.ALTIMMUNE INC - DURABLE SERUM IMMUNE RESPONSE AT SIX MONTHS COMPARED TO OVER 50% DECLINE WITH FLUZONE.ALTIMMUNE - SIX-MONTH DATA DEMONSTRATES STATISTICALLY SUPERIOR MUCOSAL IMMUNE RESPONSE PROVIDING A FIRST LINE OF DEFENSE AGAINST INFECTION.ALTIMMUNE INC - SIX-MONTH DATA DEMONSTRATES CONTINUED CLEAN SAFETY PROFILE.  Full Article

Altimmune Reports Q2 Loss Per Share Of $0.34
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.34.Q2 REVENUE $2.4 MILLION VERSUS $3.0 MILLION.AT JUNE 30, 2018, COMPANY HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $4.8 MILLION.DURING QUARTER, COMPANY RECEIVED $4.0 MILLION IN CASH RELATED TO ITS FEDERAL TAX REFUND RECEIVABLE.  Full Article

Altimmune Files For Common Units Offering Of Up To $24 Mln
Monday, 30 Jul 2018 

July 30 (Reuters) - Altimmune Inc ::ALTIMMUNE INC FILES FOR COMMON UNITS OFFERING OF UP TO $24.0 MILLION - SEC FILING.  Full Article

Altimmune Restructures Financing Agreement With Majority Of The Remaining Series B Investors
Thursday, 12 Jul 2018 

July 12 (Reuters) - Altimmune Inc ::ALTIMMUNE RESTRUCTURES FINANCING AGREEMENT WITH MAJORITY OF THE REMAINING SERIES B INVESTORS.ALTIMMUNE INC - ENTERED AGREEMENTS WITH SUBSTANTIALLY ALL REMAINING INVESTORS IN SERIES B FINANCING TO RESTRUCTURE, TERMINATE PREVIOUS ARRANGEMENTS.ALTIMMUNE INC - APPROXIMATELY 97% OF SERIES B FINANCING HAS NOW BEEN RESTRUCTURED.ALTIMMUNE - INVESTORS TO RECEIVE COMMON SHARES AS REPAYMENT OF FINAL INSTALLMENT OF SERIES B PREFERRED STOCK & TO TERMINATE OUTSTANDING WARRANTS HELD BY THEM.ALTIMMUNE - SERIES B FINANCING INVESTORS INCLUDE NOVARTIS VENTURES, HEALTHCAP, TRUFFLE CAPITAL, FIDELIS CAPITAL AND BONAVENTURE CAPITAL.  Full Article

BUZZ-U.S. STOCKS ON THE MOVE-Eventbrite, banks, oil stocks, Big Lots, Exxon Mobil, DropCar

* Eikon search string for individual stock moves: * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes fell on Friday, after data showed U.S. job growth almost stalled in February, adding to concerns of a slowdown in global growth sparked by weak China export data and a prolonged slowdown in the eurozone. At 11:42 ET, the Dow Jones Industrial Average was down 0.45 percent at 25,358.99